I agree, the SP does matter.
If you plan on staying long term, why would a BP choose to partner when we could be bought out so cheaply, I mean people are discussing a CR and on current trends it wolud be at approx 60 cents.
If on the other hand you worked for PAR, I cannot help but think you would be concerned about the SP with the upcoming AGM. If last years was a little uncomfortable for them then this years is shaping up as medieval torture.
I am aware of it being a long process as I have held for over 5 years…… as said share price is about the same and have been hearing about interested companies inquiring about partnering for the same period from PR. In fact it was about then that I recall PR stating that he is extremely grateful to retail investors…….talk is cheap, not as cheap as these blockbuster shares,
- Forums
- ASX - By Stock
- PAR
- PAR. SP
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
1.10%
!
45.0¢

PAR. SP, page-6
-
- There are more pages in this discussion • 1,113 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
45.0¢ |
Change
-0.005(1.10%) |
Mkt cap ! $174.8M |
Open | High | Low | Value | Volume |
45.5¢ | 48.0¢ | 44.0¢ | $500.6K | 1.095M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 30268 | 44.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.0¢ | 3140 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 17447 | 0.440 |
4 | 41226 | 0.435 |
6 | 54524 | 0.430 |
5 | 78564 | 0.425 |
1 | 85554 | 0.420 |
Price($) | Vol. | No. |
---|---|---|
0.450 | 3140 | 2 |
0.455 | 2000 | 1 |
0.460 | 8623 | 3 |
0.465 | 17105 | 3 |
0.470 | 2000 | 1 |
Last trade - 14.53pm 04/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online